苦参桂花汤联合介入化疗治疗晚期结肠癌及其对CCSA2和survivin表达的影响

doi:10.3969/j.issn.2095-9400.2019.11.009

Abstract
Figure/Table
References (0)
Related Citation (8)

Download: PDF (1305 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical effect of KushenGuihua Decoction combined with interventional chemotherapy in the treatment of advanced colon cancer and its effect on the expression of colon cancer specific antigen 2 (CCSA2) and survivin as tumor markers. Methods: Sixty-two patients with colon cancer in our hospital were randomly divided as experimental group (n=31) and control group (n=31). Based on the treatment with interventional chemotherapy in both groups, the experimental group was given KushenOsmanthus Decoction for 8 weeks. The improvement in traditional Chinese medicine symptoms and changes of life quality scores were evaluated in two groups. Adverse reactions and survival rate of the patients were recorded. Meanwhile, the expression of CCSA2 and survivin in both groups was detected. Results: After treatment, the traditional Chinese medicine symptoms improved; the total effective rate and the life quality score in the experimental group were better than the control group (P<0.05). Moreover, the frequency of adverse reactions in the experimental group was lower than that in the control group (P<0.05) while the survival rate was much higher (P<0.05). The expression levels of CCSA2 and survivin in the experimental group were significantly decreased after treatment. Conclusion: KushenGuihua Decoction combined with interventional chemotherapy can effectively improve the symptoms of patients with advanced colon cancer and the life quality as well. Meanwhile, it can increase the survival rate but reduce the incidence of adverse reactions in patients and inhibit the expression of CCSA2 and survivin as tumor markers.

Key words： KushenGuihua Decoction interventional chemotherapy colonic neoplasms colon cancer specific antigen 2 survivin

Received: 02 April 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Yinghua

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2019.11.009 OR https://xb.wmu.edu.cn/EN/Y2019/V49/I11/832

[1] 刘希双, 刘思良, 王光兰, 等. 结肠良恶性肿瘤的关系及其发病规律[J]. 世界华人消化杂志, 2005, 13(10): 1235-1238.
[2] 殷淑媛, 王瑞平, 邹玺, 等. 常春藤皂苷元与5-氟尿嘧啶或奥沙利铂联用对人结肠癌HT-29细胞增殖的影响[J]. 中医杂志, 2015, 56(7): 602-606.
[3] 周懿明, 徐婧, 宋怡琳. 中西医结合治疗大肠癌的研究进展[J]. 中西医结合心血管病电子杂志, 2017, 5(29): 175-176.
[4] 商斌. 介入化疗联合口服替吉奥胶囊治疗进展期胃癌的疗效和安全性分析[J]. 中国现代医生, 2014, 52(3): 146-147, 151.
[5] AKIYAMA Y, KIMURA Y, ENATSU R, et al. Advantages and disadvantages of combined chemotherapy with carmustine wafer and bevacizumab in patients with newly diagnosed glioblastoma: a single-institutional experience[J]. World Neurosurg, 2018, 113: 508-508, 514.
[6] 刘声, 王笑民, 杨国旺, 等. 扶正防癌方联合化疗对晚期结肠癌患者生活质量及免疫功能的影响[J]. 世界中医药, 2015, 10(2): 209-211, 215.
[7] 靖大道, 萧树东. 结肠癌病因学研究现状[J]. 胃肠病学, 2001, 6(4): 228-230.
[8] LEWIS C, XUN P, HE K. Response to RE: Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up [J]. Support Care Cancer, 2016, 24(10): 4081-4082.
[9] DOUILLARD J Y, ZEMELKA T, FOUNTZILAS G, et al. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study[J]. Clin Colorectal Cancer, 2014, 13(1): 14-26.
[10] 陈占涛. 补中益气汤联合化疗治疗结肠癌手术后的远期效果分析[J]. 中西医结合心血管病电子杂志, 2016, 4(14): 130-131.
[11] 赵晓宁, 薛文翰. 健脾化瘀方联合化疗治疗晚期胃癌疗效及对生活质量的影响[J]. 中医药学报, 2016, 44(3): 105-108.
[12] 王强. 扶正消积汤联合吉西他滨及顺铂治疗非小细胞肺癌临床研究[J]. 光明中医, 2017, 32(22): 3306-3307, 3326.
[13] 赵福军, 刘松江. 刘松江教授治疗大肠癌四法浅谈[J]. 中国医疗前沿, 2010, 5(20): 51-52.
[14] AMBROSINI G, ADIDA C, ALTIERI D C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997, 3(8): 917-921.
[15] 金晓昇, 安慧敏, 黄智铭. 生存素和PTEN在良恶性胃溃疡中的表达[J]. 温州医科大学学报, 2017, 47(6): 456-458.
[16] WANG T, LIU Z, ZHANG Z, et al. Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancer in vitro and in vivo[J]. Oncol Lett, 2017, 14(2): 2001-2008.
[17] LI S, YANG Y, DING Y, et al. Impacts of survivin and caspase-3 on apoptosis and angiogenesis in oral cancer[J]. Oncol Lett, 2017, 14(3): 3774-3779.
[18] IKEGUCHI M, KAIBARA N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma[J]. Br J Cancer, 2002, 87(8): 883-887.
[19] 谷化平, 尚培中, 冯骥良. 原发性胆囊癌中survivin和nm23H1表达及其临床病理的相关性研究[J]. 临床肝胆病杂志, 2006, 22(4): 252-253.
[20] SHARIAT S F, LOTAN Y, SABOORIAN H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma[J]. Cancer, 2004, 100(4): 751-757.
[21] 李志, 刘卫红, 王青, 等. 抗肿瘤相关抗原Imp1、p62、Koc、
p53、c-myc的抗体联合检测对结肠癌诊断的价值[J]. 中国卫生检验杂志, 2012, 22(7): 1484-1486.